)
Visual
test
Apellis Pharmaceuticals
Apellis Pharmaceuticals (APLS) investor relations material
Apellis Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic focus and growth outlook
Emphasis on complement pathway therapies, with SYFOVRE and EMPAVELI as key growth drivers for both near and long term.
2025 described as a foundational year, building revenue streams and pipeline for future expansion.
2026 priorities include maximizing SYFOVRE in geographic atrophy, expanding EMPAVELI in rare nephrology, and advancing next-generation therapies.
Company remains self-funded, prioritizing commercial execution, pipeline development, and capital deployment to drive revenue and profitability.
Global expansion strategies under consideration, including potential European market re-entry.
SYFOVRE: Market leadership and innovation
Maintains ~60% market share in geographic atrophy, with $587M in 2025 U.S. net product revenue and stable new patient share at 50-55%.
Five-year GALE data demonstrated durable efficacy and safety, supporting long-term use.
Prefilled syringe program and regulatory submission planned (2024–1H 2026) to enhance adoption and streamline retina practice workflow.
AI-driven functional OCT imaging and augmented reality tools enhance demonstration of patient benefit and early GA identification.
Market growth supported by improved practice flow and anticipated expansion into early-stage patient segments.
EMPAVELI: Rare disease launch and pipeline expansion
EMPAVELI approved for C3G and IC-MPGN, with >5% market penetration after first full quarter and strong early launch.
Generated $102M in FY 2025 U.S. net product revenue and demonstrated robust efficacy and safety across indications.
Launch success attributed to strong efficacy, safety profile, positive payer reception, and start form performance outpacing other rare nephrology launches.
Ongoing pivotal trials in FSGS and DGF target significant unmet needs in rare kidney diseases.
Pediatric and transplant populations show higher urgency and uptake.
SYFOVRE EMA approval strategy?
EMPAVELI 2026 growth drivers and differentiation
APL9099 tech advantages vs. gene editing peers
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income.
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Apellis Pharmaceuticals
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apellis Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for autoimmune and rare diseases. The company’s research is centered around complement inhibition, targeting the C3 protein in the complement system, which plays a key role in immune response. Apellis’ lead products and drug candidates aim to treat conditions such as geographic atrophy (a form of age-related macular degeneration) and paroxysmal nocturnal hemoglobinuria (PNH), among other serious diseases. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage